Cannabis

Thursday Aug 10, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1 The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with…

Tuesday Aug 08, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine” The company described the new patent as “strategically important” The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world’s leading oral nicotine markets This patent…

Friday Aug 04, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Incorporates New Subsidiary, Lexaria Nutraceutical Corp., for Non-Pharmaceutical, Non-Nicotine, and Non-Cannabis DehydraTECH(TM) Formulations

Lexaria Nutraceutical Corp. will keep Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets, excluding pharmaceutical, nicotine, and cannabis molecules Lexaria Pharmaceutical Corp.’s licensing was amended so as to solely focus on pharmaceutical formulations excluding nicotine Lexaria announced in early May that its nicotine trial, NIC-H22-1, had completed dosing with results expected in the near future NIC-H22-1 is anticipated to intercede…

Friday Jul 28, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Newly Granted Patent for DehydraTECH(TM)–Nicotine by United States Patent and Trademark Office

Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is expected to grow to $11.91 billion by 2029, driven by the growing ban on e-cigarettes worldwide The white pouch…

Wednesday Jul 26, 2023 - 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet

Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits Lexaria is also actively seeking…

Monday Jul 24, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science

The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1% The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension Company…

Thursday Jul 20, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities

Lexaria is a global innovator in drug delivery platforms with an expanding portfolio of patents that currently stands at 34 granted patents and many patents pending worldwide These patents pertain to the company’s method of improving bioavailability and taste as well as the use of DehydraTECH(TM) as a delivery platform for a wide variety of active pharmaceutical ingredients (“APIs”) The company has, since June 2015,…

Monday Jul 17, 2023 - 12:00 pm

The Much-awaited Cannabis Drinks Expo Returns to Chicago

Cannabis professionals, business owners, investors, researchers, and industry leaders are invited to attend the Cannabis Drinks Expo to be held in Chicago, IL on August 1, 2023. The much-awaited event is set to bring together the greatest and brightest minds in the cannabis-infused beverages industry. As the leading event for the cannabis drinks industry, Cannabis Drinks Expo (“CDE”) offers a unique platform for distributors, retailers,…

Friday Jul 14, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11% Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending…

Thursday Jul 13, 2023 - 10:30 am

4th Annual Cannabis Drinks Expo, San Francisco

Cannabis enthusiasts, investors, business executives, researchers, and industry leaders are invited to attend the 4th Annual Cannabis Drinks Expo to be held in San Francisco, CA on July 27, 2023. As the cannabis industry gains progress and modernization, the premier Expo is set to showcase innovative products with a specific focus on cannabis-infused beverages. The Cannabis Drinks Expo is a highly anticipated event for industry…

Tuesday Jul 11, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023 The company also noted its $2 million…

Wednesday Jul 05, 2023 - 9:00 am

The 2023 Alternative Products Expo, Dallas Chapter – “Everything Counterculture Under One Roof”

ZJ Events is proud to announce the third leg of its four-part Alternative Products Expo – the Dallas Chapter – that will be held at the Kay Bailey Hutchison Convention Center Dallas. The expo, which promises to be the ultimate event for anyone in the counterculture industry, will serve as a melting pot for everything counterculture, with featured products including CBD, mushrooms, nicotine replacement, dietary…

Friday Jun 30, 2023 - 2:40 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight

Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy Lexaria’s eight peer-reviewed publications support the company’s pursuit of launching an FDA-registered IND program to formally investigate DehydraTECH(TM)-CBD for hypertension The global cardiovascular drug market was worth $146.5 billion and is expected to reach $173.5 billion in 2026 – making patent protection…

Wednesday Jun 28, 2023 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US

Lexaria Bioscience recently received four new patents granted in Canada and the United States In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide The strong portfolio gives the company…

Thursday Jun 22, 2023 - 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Findings in Diabetes Animal Study and Two Other R&D Programs

Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented…

Thursday Jun 15, 2023 - 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

In May, Lexaria made a number of positive announcements related to its R&D initiatives In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1 Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in…

Friday Jun 09, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none…

Monday Jun 05, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Animal Study Showing Its Patented DehydraTECH(TM) Technology Significantly Enhances Oral Delivery of Estradiol; Raises $2 Million in Gross Proceeds from Public Offering

Lexaria recently completed its animal study HOR-A22-1 showing its patented DehydraTECH(TM) technology dramatically enhanced the oral delivery of estradiol, a type of estrogen hormone The use of DehydraTECH resulted in ~900% higher peak concentration of estradiol in the bloodstream compared to the control, as well as a 2,000% increase in the levels of estrone Estrone is a type of estrogen that can be reversibly made…

Wednesday May 31, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Finalizes DehydraTECH(TM)-CBD Batch Manufacturing for IND Filing This Summer and FDA Phase 1b Trial Commencement in October 2023

Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study This is in line with the company’s IND filing with the FDA, which it looks to complete this summer, with potential authorization within 60 days FDA authorization will mark the commencement of Phase 1b trial patient dosing, with the study…

Friday May 26, 2023 - 10:30 am

The Green Label Expo: Las Vegas 2023 Edition

The Green Label Expo 2023 edition will be held at the World Market Center in Las Vegas on the 13th & 14th of September, welcoming thousands of CBD experts, alternative product professionals, counterculture experts, and business owners to discover a vast array of global suppliers in trending sectors such as beauty, health & wellness, pet products, foods, business services, and more. As the need for…

Friday May 26, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Shareholders Approve Board Appointments Amid Push for Diversity; Vote to Endorse 6 Agenda Items in 2023 Annual Shareholder Meeting

Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023 On the agenda were the election of six director nominees, the ratification of the appointment of the company’s independent registered public accounting firm, and the approval of a one-time repricing of specific issued stock options, among others All items presented received approval, with the highest approval percentage standing at 97.6% and the lowest…

Tuesday May 23, 2023 - 11:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering Earlier the company was granted four new patents, bringing its total to 32 granted and many more pending worldwide for its patented DehydraTECH(TM) technology Lexaria…

Monday May 22, 2023 - 11:15 am

Lift Toronto 2023 Conference & Expo: Lifting the Rapidly Expanding Cannabis Industry & Community

Cannabis industry leaders, entrepreneurs, policymakers, service providers and consumers are all invited to attend the Lift Toronto 2023 Conference & Expo to be held at Metro Toronto Convention Centre from June 1-3, 2023. The advocacy-oriented, strategy-focused Lift Cannabis Business Conference (“LCBC”) on June 1st kicks off the three-day event and is dedicated to discussing best practices in evolving cannabis industry topics, brushing up on policy…

Monday May 22, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than leading oral nicotine brands Through previous animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of…

Friday May 19, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

Lexaria's patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors Lexaria recently announced the completion of its diabetes animal…

Tuesday May 16, 2023 - 9:45 am

Lift Toronto 2023 Cannabis Conference & Expo Promises to Energize, Inspire, Educate, and Motivate Audiences from Across the Cannabis Ecosystem

In October 2018, Canada became the first developed country to legalize recreational cannabis for adult use (https://ibn.fm/xofpU). Aimed at curbing the illicit trade of the drug and launching a new source of economic growth, this move is playing a significant role in the economy. For instance, Deloitte’s study, which considered the direct, indirect, and induced economic activities, estimated that the industry had contributed US$43.5 billion…

Tuesday May 16, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more Patient dosing is set to kick off as soon as possible once the expected FDA IND…

Friday May 12, 2023 - 9:45 am

Lift Toronto 2023 Cannabis Conference & Expo Connects Brands, Investors, Growers & Consumers from Across the Cannabis Industry

Cannabis industry growers, processors, manufacturers, brands, budtenders, retailers, educators, advocates, regulators, consumers, investors, and more, are invited to attend the Lift Toronto 2023 Cannabis Conference & Expo to be held June 1-3, 2023, at the Metro Toronto Convention Centre. The three-day event will begin on Thursday, June 1, with the Lift Cannabis Business Conference (“LCBC”), an all-business strategy forum focused on generating meaningful change and…

Thursday May 11, 2023 - 9:45 am

BizCann Expo: An Elite Business & Networking Event for All Things Cannabis

BizCann Expo, a must-attend event for anyone working in the cannabis space, will be held in the city of Medellín, Columbia, May 20-21, 2023, a beautiful location surrounded by the spectacular Andes mountains. Colombia’s location an1d promising regulatory environment make it a rich location for the cannabis industry, with Medellin and nearby regions guiding its growth. BizCann is the leading event in South and Latin…

Tuesday May 09, 2023 - 9:45 am

BizCann Expo Spearheading Innovation, Entrepreneurship, and Education on All Aspects of The Cannabis Industry in South and Latin America

ZJ Events invites you to the much-anticipated BizCann Expo, the premier event in South and Latin America focused on spearheading innovation, entrepreneurship, and education on all aspects of the cannabis industry. Scheduled for May 20-21, 2023, the two-day in-person event is a gathering for the cannabis industry’s best – growers, entrepreneurs, license holders, investors, industry newcomers, legal advisors, c-level executives, and service providers. It promises…

Monday May 08, 2023 - 12:00 pm

The Third Annual NECANN Illinois Cannabis Convention – The Only B2B Convention in Illinois

NECANN, a pioneer in developing engaging conventions for the cannabis industry, is proud to announce its third edition of The Illinois Cannabis Convention being held on June 2-3rd, 2023. This year’s event will build on the success of the 2022 Illinois Cannabis Convention, with scaled-up operations that will see even more exhibitors, presenters, products, and even attendees in what promises to be the best B2B…

Monday May 08, 2023 - 11:15 am

The 2023 Alternative Products Expo – Everything Counterculture Under One Roof

ZJ Events is proud to announce the 2023 Alternative Products Expo, the ultimate gathering for smoke shop owners, independent retailers, buyers, and counterculture enthusiasts. This event looks to build on the success and momentum of previous events dating back to 2019, which have achieved massive success and offered incredible value and exposure to attendees. The Alternative Products Expo offers an avenue for anyone in the…

Monday May 08, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio

Lexaria has received notifications of four new patents either awarded or allowed After the awarding of these patents, Lexaria's total patent portfolio will have grown to 32 granted patents worldwide The new granted patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents The new granted Australian patent is under Patent Family #18: Compositions and Methods for Enhanced Delivery…

Thursday May 04, 2023 - 9:45 am

NECANN Connecticut Cannabis & Hemp Convention to Deep Dive Into the Rapidly Changing Cannabis Industry

The 2023 Connecticut Cannabis & Hemp Convention is being held at one of the most prestigious locations in Connecticut, the XL Center, 1 Civic Center Plaza in Hartford, CT on May 20-21, 2023. NECANN takes note of reputable brands, as well as creative entrepreneurs on the scene, to create a vibrant blend of exhibitors, speakers, and panelists, that keep attendees engaged and inspire repeat visits…

Wednesday May 03, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Recent Research Report by Zacks SCR

Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms The report discusses the company’s ongoing research and development (“R&D”) programs, forecasting penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories Lexaria is targeting conditions with significant market potential, including hypertension, diabetes, dementia, and seizures These programs position the company for entry into collaborative opportunities…

Friday Apr 28, 2023 - 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology

Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome The success of this study inches Lexaria closer to capitalizing…

Thursday Apr 27, 2023 - 10:30 am

Lift Toronto 2023 Promises to Drive Meaningful Change and Sustainable Growth in Cannabis Industry while Providing Memorable Experiences

Lift Events & Experiences, a collective known for organizing Canada’s number-one cannabis industry conferences and trade shows, invites cannabis retailers, licensed producers, growers, budtenders, brands, investors, and everyday folks, for the Lift Toronto 2023 event scheduled for June 1-3, 2023 at the Metro Toronto Convention Centre (“MTCC”). The three-day action-packed convention is set to continue a tradition that has become synonymous with each of Lift…

Monday Apr 17, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company He has emphasized how profitable new licensing agreements could be for the…

Wednesday Apr 12, 2023 - 9:45 am

Lift Toronto 2023 Cannabis Conference and Expo Announces Speakers and Sessions; Registration Now Open

Thousands of cannabis industry and community members will gather at the Metro Toronto Convention Centre, June 1-3, for three high-energy days of discovery, education, entertainment and more. The highly anticipated Lift Toronto 2023 Cannabis Conference and Expo, which will bring together thousands of cannabis industry professionals and consumers from all parts of the cannabis ecosystem, returns to the Metro Toronto Convention Centre from June 1-3,…

Monday Apr 10, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking…

Articles

Articles Category: Cannabis

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions